Fujifilm announces expansion of its biopharmaceutical contract development and manufacturing business.
(WorldNews Japan)

Establishing a New Gene Therapy Drug Process Development Building and Expanding Product Facilities in Texas, USA Tokyo, Nov 14 2019 - FUJIFILM Corporation (President: Kenji Sukeno) will make a capital investment of approximately 13 billion yen in the gene therapy field, one of the priority areas for growth in the Contract Development and Manufacturing (CDMO) business, in order to further expand the contracted development and manufacturing business. The investment will include the addition of dedicated gene therapy laboratories. The new building will be part of Fujifilm Diosynth Biotechnologies (FDB) College Station, Texas campus. This site has been FDB`s Center of Excellence for gene therapy...